Having a good communication is a key role for animal health companies

On Thursday 25th, the annual conference of the Vet+I Foundation, the benchmark technology platform in animal health, an initiative that brings together all private companies and institutions in the animal health sector to work on projects for the development of emerging technologies, was held in Madrid. Numerous company executives and personalities from the sector were invited, including our General Manager César Carnicer and Luisa De Arriba, our Director of Biological R&D and regulatory.

One of the themes of the day’s presentations was communication. Communication is key because of its immediacy, which feeds the conversations of our followers and customers on the web and social networks. Digital channels are now essential and inescapable. It’s where the company’s first contacts with its prospects and customers take place, where they form their own opinion about us, whether they adhere to our values, our messages and our products or reject them. Just as we need to take care of our face-to-face verbal messages and ensure their integrity and scientific validity, we need to “communicate well” in any channel. As César Carnicer commented, “communication is the new sales force of the digital age”. Communicating well also means sharing information in a way that is transparent and understandable to the entire society, to whom we must explain disease transmission and the OneHealth concept, as well as the crucial role of veterinarians in it.

Communicating well is an essential ingredient in building trust and engagement with society and avoiding mistakes that can ruin the reputation not only of a company, but of an entire sector.

The situation with Covid and radical anti-vaccination biases in general have shown that communicating science is a delicate exercise that requires adequate knowledge and resources to avoid spreading dubious information that has not been objectively and scientifically validated. Communicating well requires that all actors in the sector have “collaborative intelligence”. Collaborative intelligence, a term coined by William Isaacs in 1999, is the ability to work together to make the best decisions. This is what the participants invited by the Vet+I Foundation intend to do.

For Syva, one of the important messages to take away from this Vet+I conference is that, if we want to achieve our mission to deliver meaningful solutions for animal health, our communication must also be meaningful to society and be delivered through channels that are meaningful to today’s customers. And that is why we have to show our collaborative intelligence.


To know more about the Vet+I conference we invite you to read this article* from Diaro Veterinario. https://www.diarioveterinario.com/t/3319624/gran-respaldo-sector-xii-conferencia-fundacion-vet-i

* This article is in Spanish, but if you allow the artificial intelligence of your browser to translate this page, anything is possible.

Photo source: #Diario Veterinario

You may also be interested in

13 May, 2024

The day after the first vaccinations in the Netherlands, Syva organised a round table in Utrecht focusing on the situation of bluetongue in this country and its BTV-3 vaccine.

Among those taking part in the day, many technical and practical questions that were answered by our experts, some of which reflected both the concern of being confronted once again with this BTV3 epidemic and a form of joy and relief at knowing that at the very moment many animals were being vaccinated.

Read more

10 May, 2024

The Belgian federal medicines agency, FAMHP, has now also authorised the use of the BTV3 vaccine developed by the Syva laboratories.

We are pleased to announce that, while Dutch veterinarians began mass vaccination on Monday 6 May, the Belgian veterinary health authorities on Wednesday 8 May authorised the use of Laboratories Syva's BTV3 vaccine under Article 110(2) of Regulation (EU) 2019/6.

Read more

26 April, 2024

Dutch authorities approved the use of the vaccine against bluetongue serotype 3 developed by Laboratorios Syva

After intensive work performed by our teams in our laboratories, an excellent coordination with the contract research organisations (CRO) which carried out the clinical trials necessary to test the vaccine's safety and efficacy, and an efficient communication with the authorities in the Netherlands, Syva Laboratories is pleased to announce that its vaccine against BTV 3 has been authorised for...

Read more